{
  "docId": "019de075-2875-74d4-8194-84b6aaf5cb83",
  "docSlug": "17078b9c485724b1d98591e3cd98aa3e",
  "documentTitle": "Kymera | Investor Presentation Deck | 60 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 60,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "TPD = Targeted Protein Degradation; PK = Pharmacokinetics; PD = Pharmacodynamics; HS = Hidradenitis Suppurativa; AD = Atopic Dermatitis.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-2875-74d4-8194-84b6aaf5cb83/5",
  "deckHref": "/decks/019de075-2875-74d4-8194-84b6aaf5cb83",
  "deckJsonHref": "/decks/019de075-2875-74d4-8194-84b6aaf5cb83.json",
  "deckAnchorHref": "/decks/019de075-2875-74d4-8194-84b6aaf5cb83#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.75
      },
      "kind": "list",
      "text": "Kymera is Building Franchises in Both Immunology and Oncology: Focus is on areas of high unmet needs and large commercial opportunity, in targets with clear degrader rationale",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0188476a-44a1-4a87-8e1a-911b51d97691",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "list",
      "text": "Validated Platform and Discovery Engine: Demonstrated predictable translation of PK, PD and Safety in 3 oncology and immunology programs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c546907-630a-460e-bde1-ade5c52d8753",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "list",
      "text": "Demonstrated TPD Can Lead to Differentiated Clinical Activity Compared to Small Molecule Inhibitors: Initial KT-474 data in HS and AD validates Kymera’s unique target selection strategy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9bd8e29f-6d52-444c-837d-c62b2e66b7b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "list",
      "text": "Successfully Applied TPD to Unmet Needs Outside of Oncology: Reported clinical impact in complex inflammatory diseases such as HS and AD",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a1231dc3-b83d-4e06-a671-74dca7425bee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "What Our Recent Accomplishments Mean for Kymera and TPD",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "621e7cea-a320-4942-99fd-dc0db17fbeb1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}